Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Changes in how genes in the immune system function may result in age-related macular degeneration (AMD), the leading cause of visual impairment in older adults, based on preliminary research conducted by National Institutes of Health (NIH) investigators.
The NEI, part of the National Institutes of Health (NIH), has become the first U.S. government agency to develop a formal collaborative research and training agreement with the United Kingdom’s National Health Service (NHS).
Treating patients with severe cases of uveitis, the fifth leading cause of vision loss in the United States, either locally with eye implants or systemically with anti-inflammatory medications improved vision similarly over two years.
Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD).
In high-risk adults with type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.